益气养阴祛瘀方联合西药治疗糖尿病肾病Ⅲ~Ⅳ期合并动脉粥样硬化气阴两虚夹瘀证临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R255.4;R256.2

基金项目:

浙江省中医药科技计划项目(2023ZL706)


Clinical Study on Yiqi Yangyin Quyu Prescription Combined with Western Medicine for Diabetic Kidney Disease in Stage Ⅲ -Ⅳ with Atherosclerosis of Qi-Yin Deficiency Complicated with Blood Stasis Syndrome
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察益气养阴祛瘀方联合西药治疗糖尿病肾病(DKD) Ⅲ~Ⅳ期合并动脉粥样硬化(AS) 气阴两虚夹瘀证的临床疗效以及对患者脂质代谢的影响。方法:选取2023年4月—2024年3月嘉兴大学附属平 湖市中医医院肾病科收治的80例DKD Ⅲ~Ⅳ期合并AS气阴两虚夹瘀证患者,依据随机数字表法分为观察组和 对照组,每组40例。研究期间,观察组脱落2例、剔除3例,对照组脱落1例、剔除2例。对照组给予西药治 疗,观察组在对照组基础上加用益气养阴祛瘀方。2组均治疗24周。评估2组中医证候疗效及安全性,比较 2组AS相关指标[颈动脉内膜中层厚度(IMT)、斑块面积]、中医证候积分、血脂指标[甘油三酯(TG)、总 胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、肾功能指标[血肌 酐(SCr)、估算肾小球滤过率(eGFR)、24 h 尿蛋白定量)] 及血糖指标[空腹血糖(FBG)、餐后2 h 血 糖(P2hBG)、糖化血红蛋白(HbA1c)]。结果:观察组中医证候疗效总有效率94.29%(33/35),高于对照组 29.73% (11/37)(P<0.05)。治疗后,2组IMT均较治疗前变薄(P<0.05),斑块面积均较治疗前缩小(P< 0.05);观察组IMT薄于对照组(P<0.05),斑块面积小于对照组(P<0.05)。治疗后,2组中医证候积分均较 治疗前降低(P<0.05),观察组中医证候积分低于对照组(P<0.05)。治疗后,2组TG、TC、LDL-C、SCr、 24 h尿蛋白定量、FBG、P2hBG、HbA1c水平均较治疗前降低(P<0.05),HDL-C、eGFR水平均较治疗前升 高(P<0.05); 观察组TG、TC、LDL-C、SCr、24 h 尿蛋白定量、FBG、P2hBG、HbA1c 水平均低于对照 组(P<0.05),HDL-C、eGFR水平均高于对照组(P<0.05)。2组均未见严重不良反应。结论:益气养阴祛瘀 方联合西药能安全有效地治疗DKD Ⅲ~Ⅳ期合并AS气阴两虚夹瘀证,调节脂质代谢紊乱,缩小斑块面积,有 助于改善肾功能,进而延缓病情进展。

    Abstract:

    Abstract:Objective:To observe the clinical efficacy of Yiqi Yangyin Quyu Prescription combined with western medicine in treating patients with diabetic kidney disease (DKD) in stage Ⅲ-Ⅳ with atherosclerosis (AS) of qi-yin deficiency complicated with blood stasis syndrome,and to evaluate its effect on lipid metabolism. Methods:A total of 80 patients with DKD in stage Ⅲ-Ⅳ with AS of qi-yin deficiency complicated with blood stasis syndrome who were admitted to the Department of Nephrology,Pinghu Chinese Medicine Hospital Affiliated to Jiaxing University from April 2023 to March 2024 were selected and divided into the observation group and the control group using the random number table method,with 40 cases in each group. During the study,two cases dropped out and three cases were excluded from the observation group, while one case dropped out and two cases were excluded from the control group. The control group received western medicine treatment,while the observation group received Yiqi Yangyin Quyu Prescription on the basis of the control group's treatment. Both groups were treated for 24 weeks. The traditional Chinese medicine (TCM) syndrome efficacy and safety were evaluated. The following parameters were compared between the two groups: ASrelated indicators [carotid intima-media thickness (IMT), plaque area], TCM syndrome scores, lipid indicators [triglycerides (TG),total cholesterol (TC),low-density lipoprotein cholesterol (LDL-C),high-density lipoprotein cholesterol (HDL-C)], kidney function indicators [serum creatinine (SCr) , estimated glomerular filtration rate (eGFR), 24-hour urinary protein quantification (24hUTP)], and blood glucose indicators [fasting blood glucose (FBG), 2-hour postprandial blood glucose (P2hBG), glycated hemoglobin (HbA1c)]. Results: The total effective rate of TCM syndrome efficacy was 94.29% (33/35) in the observation group,which was significantly higher than 29.73%( 11/37) in the control group( P<0.05). After treatment,IMT was thinner and plaque area was reduced in both groups compared with those before treatment (P<0.05);the observation group showed thinner IMT and smaller plaque area than the control group (P<0.05). After treatment, TCM syndrome scores decreased in both groups compared with those before treatment (P<0.05),with lower scores in the observation group than those in the control group (P<0.05). After treatment, levels of TG, TC, LDL-C, SCr, 24hUTP, FBG, P2hBG, and HbA1c decreased in both groups compared with those before treatment (P<0.05),while levels of HDL-C and eGFR increased compared with those before treatment( P<0.05). The observation group demonstrated lower levels of TG,TC,LDL-C, SCr, 24hUTP, FBG, P2hBG, and HbA1c, and higher levels of HDL-C and eGFR compared with those in the control group (P<0.05). No significant adverse reactions were observed in either group. Conclusion: Yiqi Yangyin Quyu Prescription combined with western medicine is a safe and effective treatment for patients with DKD in stage Ⅲ-Ⅳ with AS of qi-yin deficiency complicated with blood stasis syndrome. It helps regulate lipid metabolism,reduce plaque area,improve kidney function,and subsequently delay disease progression.

    参考文献
    相似文献
    引证文献
引用本文

吴晓芸,陈美雪,张春灵,万鸣宏.益气养阴祛瘀方联合西药治疗糖尿病肾病Ⅲ~Ⅳ期合并动脉粥样硬化气阴两虚夹瘀证临床研究[J].新中医,2026,58(2):21-27

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2026-01-29
  • 出版日期:
文章二维码